Esteve invests €100 million in new manufacturing plant in Spain
Spain-headquartered CMO Esteve expands its manufacutring capacity in plants in Girona, Spain to increase global API offerings with advanced technological solutions, through a weighty investment of €100 million.
Esteve is a leading healthcare company and pharmaceutical innovator and partner based in Spain.
Esteve has a global presence, mostly throughout Europe, but with industrial sites in China and Mexico. In Spain, Esteve has a chemical R&D centre in Barcelona, and three production plants in the Catalan region, located in Celrà (Gironès), Banyeres del Penedès (Baix Penedès), and Lliçà de Vall (Vallès Oriental). Now, they have plans to further increase manufacturing capacity in the region.
Esteve has initiated a project to construct a new manufacturing unit at its Celrà plant in Girona, with plans to invest €100 million through to 2026. The expansion aims to boost the production capacity of active pharmaceutical ingredients at its primary industrial site. Once the new facilities become operational in the latter quarter of 2026, the company will welcome approximately 100 new employees to its existing team of 370 professionals. The expansion includes building new production and service facilities and installing up to 150 m3 of reaction volume, leading to a 45% increase in Esteve's production capacity at Celrà and a 15% increase in the overall global capacity of the company.
The new unit in Girona illustrates the dedication to advancements in developing, manufacturing, and sales of APIs for CMOs. The latest technological solutions, including in digitalisation and data analysis, incorporated into the facility will ensure the efficient production of highly-potent APIs.
The facility enables the production of new products to be added to Esteve’s portfolio, which will be distributed throughout the USA, Europe, and Japan.
"Thanks to our commitment to quality, efficiency and reliability, our activity in the development and manufacturing of active pharmaceutical ingredients has experienced notable growth in recent years. The expansion of our main industrial centre will allow us to satisfy a growing global demand and expand our activity, advancing our mission of improving people's lives", commented Pere Mañé, the General Manager of Esteve Química.
Source:
[1] Esteve Química. Esteve will invest 100 million euros in the construction of a new plant at its industrial centre in Celrà (Girona). [Date accessed 09/07/2024] www.esteve.com/global/news/esteve-will-invest-100-million-euros-in-the-construction-of-a-new-plant-at-its-industrial-centre-in-celra-girona
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News CPHI Pharma Awards 2024: Meet the winners from the CPHI Celebration
This year we had a lot to celebrate, the 35th Anniversary of CPHI, and our esteemed award winners, of which we included two additional categories this year, the Future Leader award, and Woman of the Year award. -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance